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Abstract
Treatment of lung cancer is an unmet need as it accounts for the majority of cancer deaths worldwide. The
development of new therapies urges the identiﬁcation of potential targets. MicroRNAs’ expression is often deregulated
in cancer and their modulation has been proposed as a successful strategy to interfere with tumor cell growth and
spread. We recently reported on an unbiased high-content approach to identify miRNAs regulating cell proliferation
and tumorigenesis in non-small cell lung cancer (NSCLC). Here we studied the oncogenic role of miR-663 in NSCLC
biology and analyzed the therapeutic potential of miR-663 targeting. We found that miR-663 regulates apoptosis by
controlling mitochondrial outer membrane permeabilization (MOMP) through the expression of two novel direct
targets PUMA/BBC3 and BTG2. Speciﬁcally, upon miR-663 knockdown the BH3-only protein PUMA/BBC3 directly
activates mitochondrial depolarization and cell death, while BTG2 accumulation further enhances this effect by
triggering p53 mitochondrial localization. Moreover, we show that miR-663 depletion is sufﬁcient to elicit cell death in
NSCLC cells and to impair tumor growth in vivo.
Introduction
Lung cancer is a disease with enormous implications on
public health as it is nowadays the foremost cause of
cancer-related death1. Despite advances in diagnostics,
the improvement of surgical procedures and the devel-
opment of new biologic drugs, the overall survival rate for
lung cancer remains frustratingly poor2,3.
Lung cancer derives from aberrant cells of the respira-
tory epithelium. It is a heterogeneous disease that can be
divided into two subtypes: small cell lung cancer (SCLC),
a highly malignant tumor developed from neuroendocrine
cells and non-small cell lung cancer (NSCLC). NSCLC
accounts for the 85% of patients and is further divided
into three major histotypes: adenocarcinoma, squamous
cell carcinoma, and large cell carcinoma. To date the vast
majority of patients are diagnosed at advanced stages and
available therapies are often only temporarily effective.
The study of the molecular basis of lung cancer, aimed at
the identiﬁcation of novel therapeutic targets is a major
need to ﬁght this devastating disease4.
MicroRNAs (miRs) are a class of highly conserved non-
protein-coding RNAs, involved in the regulation of gene
expression5. In mammals, single-stranded miRs bind to
partially complementary target sequences on speciﬁc
mRNAs (usually in the 3′ untranslated region -3′ UTR)
thus inhibiting translation and/or promoting mRNA
degradation6. In the last decades, the deregulation of miR
function has been linked to cancer occurrence, progres-
sion and metastasis7,8. In particular, it has been shown
© The Author(s) 2018
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: MicolE Fiori (ﬁorimicol@gmail.com) or
Ruggero De Maria (Ruggero.DeMaria@unicatt.it)
1Institute of General Pathology, Catholic University of the Sacred Heart and
Gemelli Polyclinic, Rome, Italy
2Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità,
Rome, Italy
Edited by E. Candi
Ofﬁcial journal of the Cell Death Differentiation Association
12
34
56
78
90
12
34
56
78
90
that miRs can act as oncogenes and/or oncosuppressors
in a tissue-speciﬁc manner, envisaging the possibility to
develop new anti-cancer strategies based on miRs’
expression modulation. The ability of miRs to orchestrate
a complex network of interactions by concurrent target-
ing of several mRNAs endows these molecules with a
great regulatory potential, allowing a kind of resetting of
the cellular fate by interfering with a single miR9.
Programmed cell death or apoptosis is a pivotal
mechanism in the development of multicellular organisms
and tissue homeostasis maintenance. Inappropriate
apoptosis leads to several human pathologies including
many types of cancer. Tumor spread entails the escape
from apoptotic response and regulators of apoptosis are
often mutated in cancer10,11. Abundant literature has
highlighted that miRs regulate apoptosis at different
levels, envisaging the possibility to control cell death
through miR modulation.
We have recently investigated the role of all known
miRNAs in NSCLC through the neutralization of their
function, taking advantage of a locked nucleic acid (LNA)-
based anti-miRNA library (miRCURY LNA microRNA
inhibitor library, Exiqon, Vedbaek, Denmark)12. We
identiﬁed a number of miRs whose knock-down impairs
NIH-H460 lung cancer cell survival and/or proliferation
and classiﬁed them as bona ﬁde oncogenes. Among the
top 20 hits, we focused on miR-663 showing that it is a
key regulator of the apoptotic cascade through its direct
targets PUMA/BBC3 (p53 up-regulated modulator of
apoptosis/Bcl-2 binding component 3) and BTG2 (B-cell
translocation gene 2). In NSCLC miR-663 allows cancer
cells to escape apoptosis, thus promoting tumor onset and
propagation. We propose miR-663 as novel therapeutic
target as its neutralization leads to cell death in vitro and
reduces tumor growth in vivo.
Results
miR-663 inhibition impairs NSCLC cell proliferation and
tumor growth in vivo
As a result of anti-miR-LNA library screening in NIH-
H460 cells, miR-663 listed among the top 20 hits endowed
with oncogenic features. We ﬁrst performed some in vitro
experiments to conﬁrm the screening results. Neu-
tralization of miR-663 by LNA transfection was able to
impair NIH-H460 cells viability (Fig. 1a, b) and
anchorage-independent growth (Fig. 1c), inferring a pro-
tumoral role of miR-663. We tested whether miR-663
function was necessary for other NSCLC cells by knock-
down experiments in A549, Calu-1, and H1299 cells
(Fig. 1e, f and Fig. S1). The four assayed cell lines repre-
sent different histological subtypes of NSCLC, distinct
tissues of origin and diverse mutational status (Table S1).
As shown in Fig. 1 (panels d–f), LNA-663 treatment sig-
niﬁcantly reduced cell growth in all the systems tested,
suggesting that this miRs commonly behaves as an
oncogene in NSCLC. Further, we tested the effect of miR-
663 depletion in patient-derived cells grown as tumor-
spheres, conﬁrming the pro-tumoral role of miR-663 in
this system (Fig. S2a and data not shown). We next
investigated if interfering with miR-663 function could
represent an effective strategy to hamper tumor growth
in vivo. To test this hypothesis CD1 nude mice were
subcutaneously injected with NIH-H460 cells. When
tumors became palpable (~40 mm3), LNA-663 was locally
administered every 3 days, in four doses of 15 mg/kg.
Growth curve of LNA-663-treated versus control tumors
showed a signiﬁcant reduction in mass expansion that
lasted after treatment completion, as shown also by tumor
weight measured ex vivo (Fig. 1g, h and Fig. S1e).
miR-663 controls apoptosis in NSCLC cells
Sustained by the above data, we deepened our analysis
to better understand the role of miR-663 in NSCLC.
FACS analysis of miR-663 knockdown cells showed an
increase of the sub G0 fraction, suggestive of apoptosis
(Fig. 2a, b). Annexin V staining conﬁrmed that miR-663
inhibition triggers programmed cell death (Fig. 2c, d).
Moreover, the appearance of cleaved PARP-1 and cleaved
Caspase 3 already 16–24 h post LNA-663 transfection
demonstrated that the kinetics of apoptotic cascade
induction is extremely rapid (Fig. 2e), suggesting a direct
effect on cell death effectors. Apoptosis induction upon
miR-663 deprivation was observed also in other lung
cancer cell lines (Fig. S2). Altogether, these data indicate
that the oncogenic role of miR-663 in NSCLC cells
implicates the control of apoptosis.
PUMA is a direct target of miR-663
In order to identify miR-663 targets that mediate apop-
tosis induction, in silico analyses were conducted taking
advantage of the algorithms TargetScan, RNA22 and
miRanda. In particular, we focused on positive regulators of
apoptosis and selected PUMA/BBC3 among predicted
targets. Identiﬁed in 2001, this gene was characterized as
activator of both p53-dependent and p53-independent
apoptosis13–17. It belongs to the BH3-only subclass that
regulates canonical mitochondrial apoptosis: upon internal
or external stimuli, PUMA binds to inhibitory members of
Bcl-2 protein family displacing Bak and Bax and thus
triggering mitochondrial outer membrane permeabilization
(MOMP) and caspase activation18,19. Interestingly, the
genomic region 19q13.3 entailing the PUMA/BBC3 gene is
often deleted in human cancer13,18,20.
In Fig. 3a is shown the putative miR-663-binding site on
PUMA 3′UTR. The inverse correlation of expression of
miR-663 and PUMA was demonstrated by knock down
experiments: a marked increase in protein level was found
when cells were treated with LNA-663 (Fig. 3b). To
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Fig. 1 miR-663 inhibition impairs cell viability and tumorigenic potential of NSCLC cells. a Cell viability of NIH-H460 cells measured 72 h post
transfection with 25 nM cntrl LNA or LNA-663. b Growth curve of NIH-H460 cells untreated (nt) and transfected with LNA-663 at 25 nM; as in panel (a),
cell number was assessed by Cell Titer Glo assay at the indicated time points after transfection. c Clonogenic capacity of NIH-H460 cells after anti-miR-
663 treatment; the graph shows the percentage of plated cells that gave rise to colonies. d Cell viability of A549 cells measured 72 h post transfection
with LNA-663 (100 nM). e, f Growth curve of Calu-1 and H1299 cells untreated (nt) and transfected with LNA-663 at 25 nM. g 2*105 NIH-H460 cells
were injected in the ﬂank of CD1/nude mice. After tumors had reached a palpable volume, LNA-663 was locally administered (15 mg/kg) at the
indicated time points (red arrows). Shown is the tumor growth of LNA-treated xenografts versus PBS vehicle, as deﬁned by mass volume—mean ± s.
e.m., n = 8. h Tumors were explanted and weighted at the end of the experiment. Shown is the mean tumor weight for each group. Mean ± s.e.m.,
n = 8 *** p < 0.001, *p < 0.05
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evaluate the possible contribution of transcriptional acti-
vation by p53 to PUMA accumulation, mRNA levels were
monitored by qPCR. Surprisingly, despite overall
p53 stabilization observed by western blot, PUMA mRNA
levels resulted unaffected by miR-663 modulation, cor-
roborating the hypothesis of a miR-dependent post-
transcriptional regulation (Fig. S3a-b). Further, PUMA
upregulation upon miR-663 depletion was observed also
in p53-NULL cells Calu-1 and H1299 together with
PARP-1 cleavage, indicative of apoptosis (Fig. 3c). To
verify the direct interaction between miR-663 and PUMA
mRNA, the 3′UTR was cloned downstream of the renilla
luciferase gene in the psiCHECK-2 vector (Promega) and
co-transfected with a miR-663 mimic. Furthermore, to
validate target speciﬁcity, PUMA 3′UTR mutant deriva-
tive was generated where the putative miR-663 binding
site was deleted (base pairing with miR-663 seed
sequence was abolished by deleting the nucleotides
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Fig. 2 miR-663 depletion induces apoptosis. The percentage of apoptotic NIH-H460 cells upon transfection with LNA-663 at 25 nM was analyzed
by FACS and is shown as sub-G0 fraction. a one representative experiment, b mean of four independent experiments. Mean ± s.d. Annexin V staining
showing apoptosis induction 72 h after LNA-663 transfection; c one representative experiment, d mean of two independent experiments. Mean ± s.
d., e PARP-1 and CASPASE 3 cleavages at the indicated time points after LNA-663 transfection is shown by immunoblot.**p < 0.01, *p < 0.05
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marked in red—Fig. 3a). Reduction in luciferase activity
upon miR-663 overexpression was observed in the pre-
sence of wild type PUMA 3′UTR, while the mutated
construct was unaffected by miR-663 levels, indicating
that PUMA is indeed a bona ﬁde target of miR-663
(Fig. 3d). PUMA knock-down by siRNA was able to
relieve the LNA-663-induced phenotype on cell viability,
further highlighting the pivotal role of this target in
apoptosis induction (Fig. 3e and Fig. S3c). However, the
partial rescue obtained by this approach suggests a
cooperative action of PUMA with other unidentiﬁed miR-
663 targets.
BTG2 is a novel direct target of miR-663
To better characterize the network of molecular inter-
actions orchestrated by miR-663 and possibly identify
novel direct targets, we performed transcriptome analyses
by microarrays in NIH-H460 cells treated with LNA-663
(Whole Transcript Expression Arrays, HuGene 1.0 St,
Affymetrix).
We used an integrative approach combining microRNA
target predictions by TargetScan (release 5.2) and the list
of 568 genes that resulted upregulated ≥1.5 fold by gene
arrays upon miR-663 depletion (Fig. 4a, b and Tables S2,
S3). As a positive control of our system, we employed the
miR-663 known target p21 (CDKN1A) that resulted
upregulated upon miR knockdown (3.02 mean fold
induction, p< 0.01) and ranked at third position in
overlaid datasets (Fig. 4a, b and Tables S2,3). We ﬁrst
conﬁrmed p21 protein accumulation after miR-663 knock
down (Fig. S4a). Moreover, we found that p21 mediates
the effect of LNA-663 on NSCLC cells, as impairment of
p21 upregulation by siRNAs was able to partially rescue
cell viability/proliferation of miR-663-depleted cells
(Fig. S4b). In nasopharyngeal carcinoma, it was reported
that induction of p21 upon miR-663 knockdown leads to
cell cycle arrest in G1 phase, while no apoptosis was
described21. We therefore assumed that the rescue
observed by combining LNA-663 with siRNAs against
p21 is due to miR-663 regulation of G1/S phase transition
e)
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Fig. 3 PUMA is a direct target of miR-663. a Predicted PUMA 3′UTR binding site for miR-663. The alignment of the seed region of miR-663 with
PUMA 3′ UTR is shown. The sites of target mutagenesis are indicated in red. b, c Immunoblot showing inverse correlation of PUMA and miR-663
expression paralleled by PARP-1 cleavage in NIH-H460 b Calu-1 and H1299 cells c. d Luciferase activity in HeLa cells transfected with PUMA UTR wt or
mut in combination with a control or miR-663 mimic. The normalized luciferase activity is indicated—mean ± s.e.m., **p = 0.008. e Downmodulation
of PUMA by RNA interference can rescue LNA-663 apoptotic effect in NIH-H460 cells as shown by Cell Titer Glo assay. Mean ± s.d., ***p < 0.001,
*p < 0.05
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and thus to an increased cell proliferation rather than to
the reduction of cell death. Since in NSCLC miR-663
inhibition leads to a quick and massive induction of
apoptosis, we reasoned that p21 plays a marginal role and
focused our efforts on novel hypothetical targets con-
trolling programmed cell death.
The ﬁrst putative target upregulated upon miR-663
depletion was TP53INP1 (tumor protein p53 inducible
nuclear protein 1), an antiproliferative and proapoptotic
protein induced by p53 that acts as a mediator of cell
response to stress22–24. TP53INP1 protein levels resulted
unaffected by miR-663 knock down concluding that it is
not directly modulated by this microRNA (Fig. S4c,d).
The second candidate in our combined list was the
putative target BTG2, which listed among top ﬁve upre-
gulated genes (5.44 mean fold induction, p< 0.01) sug-
gesting a possible direct correlation with miR-663 levels
(Fig. 4a, b). Consistently, knockdown of miR-663 by LNA
increased BTG2 expression at both mRNA and protein
levels in NIH-H460 cells (Fig. 5a, b). The role of BTG2 has
been extensively studied. BTG2 acts through multiple
mechanisms regulating transcription, differentiation, and
PUTATIVE TARGETS UPREGULATED 
UPON miR-663 KNOCK DOWN
GENE NAME FOLD INDUCTION
TP53INP1 5.73
BTG2 5.44
CDKN1A 3.02
RPL27A 2.82
PDRG1 2.42
YPEL3 2.32
RGAG4 2.26
RPL27A 2.18
JUNB 1.90
PORCN 1.89
FAM90A1 1.85
ZNF385A 1.75
FOSB 1.73
FAM90A1 1.67
ZNF345 1.64
CITED2 1.64
PLCXD1 1.62
TAF8 1.61
PI4K2A 1.61
PDPK1 1.60
NRARP 1.59
ZNF543 1.59
NOL3 1.54
NPTX1 1.53
ICK 1.52
LCN1 1.51
CEBPB 1.51
TBC1D22B 1.51
C17orf39 1.51
b)a)
26
Fig. 4 Identiﬁcation of novel miR-663 target genes. a Unsupervised hierarchical clustering of genes that are signiﬁcantly upmodulated upon miR-
663 depletion (≥1.5 fold increase); genes in the heatmap are shown starting from the most upregulated to the most downmodulated one. The top
50 genes are shown. The arrow indicates BTG2 and the star CDKN1A/p21. b Venn diagram showing the integrated analysis of putative miR-663 target
genes and top 568 upregulated genes ( > 1.5 fold) upon miR-663 knock down. Twenty-six identiﬁed putative target genes of miR-663 are listed in the
table together with relative fold increase as measured by gene arrays
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development25–27. Moreover, it is an oncosuppressor gene
in cancer cells, controlling cell cycle progression, DNA
damage repair, and apoptosis. Noteworthy, BTG2
expression was found downregulated in many human
cancers28–32.
To verify whether miR-663 directly binds to BTG2 3′
UTR, the region ﬂanking the miR putative binding site
was cloned in psiCHECK-2 vector and luciferase assay
was performed. A mutant construct lacking the eight
nucleotides recognized by the miR seed sequence was
used as a control (Fig. 5c). Co-transfection of wt UTR
together with a miR-663 mimic in HeLa cells caused a
consistent decrease of luciferase activity, that was abol-
ished when using the mutant construct (Fig. 5d),
demonstrating that miR-663 indeed targets BTG2.
BTG2 plays an essential role in miR-663-mediated
apoptosis control
To evaluate the role of BTG2 in miR-663-mediated
control of apoptosis, we neutralized LNA-663-induced
BTG2 overexpression by siRNAs (Fig. 6a, b). NIH-H460
cells treated with both LNA-663 and BTG2 siRNAs
showed a milder reduction of cell viability if compared
with LNA-663-treated cells, suggesting that this target
actively determines the apoptotic phenotype (Fig. 5e). It
has been previously shown that BTG2 overexpression can
lead to programmed cell death through direct binding to
PIN-1 (protein-interacting NIMA): upon BTG2 binding,
PIN-1 translocates from nucleus to cytoplasm, where it
leads to mitochondrial membrane depolarization33,34.
PIN-1 interacts with and regulates the activity of several
e)
)b)a
BTG2 3’ UTR wt 5' -...GCCCUUCCGC- – – – CCCCGCCC…– 3’
|  |  |  |              |  |  |  |  |  | | 
miR-663                   3' - CGCCAGGGCGCCGCGGGGCGGA – 5’
c)
LNA
TUBULIN
BTG2
nt cntrl       663
cleaved
PARP-1
49 KDa
17KDa
14 KDa
98 KDa
d)
Fig. 5 BTG2 is a direct target of miR-663. a q-RT-PCR showing inverse correlation of BTG2 mRNA and miR-663 expression. GAPDH was used for
PCR normalization—mean ± s.d.; b Western blotting showing the upmodulation of BTG2 protein upon miR-663 neutralization, paralleled by PARP-1
cleavage. TUBULIN was used as protein loading control. c Predicted BTG2 3′ UTR binding site for miR-663. The alignment of the seed region of
miR-663 with BTG2 3′ UTR is shown. The sites of target mutagenesis are indicated in red. d Luciferase activity in HeLa cells transfected with BTG2
UTR wt or mut in combination with a control or miR-663 mimic. The normalized luciferase activity is indicated—mean ± s.e.m.***p = 0.0004.
e Downmodulation of BTG2 by RNA interference can rescue LNA-663 apoptotic effect in NIH-H460 cells as shown by Cell Titer Glo assay—mean ± s.d.
***p < 0.001, *p < 0.05
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Fig. 6 miR-663 controls PIN-1-mediated apoptosis and p53 mitochondrial function. a Immunoblot showing BTG2 downmodulation 72 h after
siRNA transfection. TUBULIN was used as protein loading control. Normalized BTG2 levels are expressed as fold decrease relative to cntrl treated cells.
bWestern blotting showing BTG2 modulation in NIH-H460 after the indicated treatments. Double transfection of anti-BTG2 siRNA together with LNA-
663 restores BTG2 levels of control cells, counteracting LNA-mediated induction. PARP-1 cleavage is reduced to 60%. TUBULIN was used as protein
loading control. Numbers indicate BTG2 levels fold change relative to cntrl treated cells, and cleaved PARP-1 levels fold decrease relative to LNA-663/
cntrl siRNA-treated cells. The values were normalized to TUBULIN signal, as measured by densitometric analyses. c Subcellular BTG2 and PIN-1
localization in NIH-H460 cells treated with control LNA or LNA-663 was assessed by immunoﬂuorescence staining. d Mitochondrial membrane
potential of NIH-H460 cells upon miR-663 downmodulation was measured by JC-1 staining. An increase of the ratio between green and red signals is
indicative of membrane depolarization typical of apoptotic cells. e Western blotting showing PIN-1 modulation in NIH-H460 subcellular fractions 24 h
after LNA-663 treatment. Cytoplasmic accumulation and nuclear decrease of PIN-1 are expressed as fold changes relative to cntrl-treated cells. The
histogram shows the ratio between cytoplasmic and nuclear signal. f Immunoblot of p53 in NIH-H460 subcellular fractions. Hsp90 and Bcl-2 were
used as cytoplasmic and mitochondrial markers, respectively. Mitochondrial p53 modulation is expressed as fold increase relative to cntrl treated cells
and normalized to Bcl-2 signal
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proteins by inducing cis-trans isomerization. Noteworthy,
PIN-1 is considered a master regulator of mitochondrial
apoptosis35. One of the mechanisms of apoptosis induc-
tion by PIN-1 involves a non-canonical role of p53. In
particular, it has been shown that PIN-1 induces a con-
formational change of cytoplasmic p53, thus reducing its
afﬁnity for MDM2 and leading to cytoplasmic accumu-
lation of mono-ubiquitinated p53. Under these condi-
tions, p53 translocates to the mitochondrial membrane,
where it behaves as a BH3-only protein interacting with
Bcl2 family members and inducing MOMP, with a
kinetics that is faster than p53 transcriptional program
activation34–39. Cytoplasmic PIN-1 is therefore regulating
transcription-independent p53 induction of apoptosis.
To determine whether miR-663 inhibition was sufﬁcient
to affect PIN-1 localization, we conducted immuno-
ﬂuorescence analyses, which showed that down-
modulation of miR-663 induces BTG2 overexpression
and cytoplasmic diffusion that is accompanied by PIN-1
nuclear exit, as conﬁrmed also by western blot (Fig. 6c, e
and Fig. S5). These events eventually lead to mitochon-
drial membrane depolarization characteristic of apoptosis,
as shown by monitoring mitochondrial membrane
potential with JC-1 staining (Fig. 6d). By western blot
analyses of intracellular fractions we observed overall
p53 stabilization and concomitant mitochondrial locali-
zation upon miR-663 depletion (Fig. S2a and Fig. 6f). To
establish whether this process is indeed dependent on
BTG2, we performed knockdown experiments. siRNAs
signiﬁcantly reduced BTG2 expression while double
treatment with LNA-663 and siRNAs restored BTG2
protein levels of control cells, counteracting LNA-663-
mediated BTG2 induction (Fig. 6a, b). Under these con-
ditions, p53 accumulation on mitochondria is impaired
and apoptosis induction decreased (Fig. 6b–e). Further we
explored BTG2 role in the absence of p53 to establish
whether other BTG2-dependent mechanisms (involving
or not PIN-1) are relevant for apoptosis induction35. We
veriﬁed that in p53-NULL cells BTG2 is upregulated upon
miR-663 downmodulation (Fig. S6a–d). However, by RNA
interference we were not able to rescue the effect on cell
viability of LNA-663 treatment (Fig. S6e–h), suggesting
that the role of BTG2 is not relevant in the absence of
functional p53.
In conclusion, these data reveal that miR-663 exerts a
pivotal role in apoptosis regulation of NSCLC cells, con-
trolling convergent mechanisms of MOMP through the
identiﬁed target genes PUMA and BTG2.
Materials and methods
Cell culture
Human NSCLC A549 and Calu-1 (American Type
Culture Collection—ATCC, Manassas, VA, USA) were
grown in DMEM, whereas HeLa, NIHH460, and H1299
(ATCC) in RPMI 1640 (Lonza, Basel, Switzerland). All cell
media were supplemented with 10% heat-inactivated fetal
bovine serum (PAA, Pasching, Austria). Patient-derived
NSCLC cells were isolated from tumor specimens and
grown in suspension as tumorspheres in a serum-free
medium supplemented with 20 ng/ml EGF and 10 ng/ml
bFGF (Peprotech), as previously described40.
Transfection experiments
Transfection experiments with oligonucleotides (siR-
NAs, miR-mimics, and LNAs) were performed using
HiPerFect transfection reagent (Qiagen), following man-
ufacturer’s instructions. LiPofectamine 2000 (Invitrogen)
was used for transfections with DNA constructs. All
siRNAs were used at the ﬁnal concentration of 25 or 50
nM. PUMA/BBC3 siRNAs were purchased from Qiagen
(FlexiTube siRNAs #2 and #3, SI02655520 and
SI02822820, respectively), whereas BTG2 siRNA from
Dharmacon (ON-TARGET plus, Set of 4 Upgrade
LU-012308-00, siRNA #5). The miR-mimics (Qiagen)
were used at the ﬁnal concentration of 30 nM and the
LNAs (Exiqon) at the ﬁnal concentration of 25 or 50 nM.
Anchorage-independent growth assay
Cells were seeded in 24-well plates and transfected with
indicated LNAs at the ﬁnal concentration of 25 nM.
Twenty-four hours post-transfection cells were trypsi-
nized and counted with trypan blue exclusion. A total of
500 healthy cells were resuspended in 1.5 ml semisolid
medium consisting of RPMI 1640 supplemented with 10%
FBS and 0.3% Agar Noble (Difco, Kansas City, Missouri)
and plated on solidiﬁed 1.5 ml RPMI 1640 supplemented
with 10% FBS and 0.6% Agar Noble. Colonies formation
was assessed after 2 weeks upon crystal violet staining
(Fluka, St. Gallen, Switzerland) and manual counting at
the microscope.
Cell proliferation and apoptosis detection
For proliferation assay, cells were seeded at the same
density (2× 103 cells/well) in 96-well plate and transfec-
tion was performed using HiPerFect reagent (Qiagen) and
50 nM LNAs (Exiqon). At the indicated time points, three
wells for each condition were analyzed. Growth curves
were generated by evaluating cell number with CellTiter-
Glo Luminescent Cell Viability Assay (Promega), follow-
ing manufacturer’s instructions.
Apoptosis was measured with the Apoptosis Detection
Kit (MBL International, Woburn, MA). Brieﬂy, 4× 104
cells were seeded in 24-well plate and transfected with
control LNA and LNA-663; at the indicated time points
cells were harvested, counted, and stained with Annexin
V-FITC and PI (5 µg/ml) and analyzed using a BD FACS
Canto Cytometer (Becton Dickinson, San Jose, CA). In
addition, the percentage of apoptotic cells was assessed
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also by detecting the sub-G0 fraction upon incubation
with Nicoletti buffer (0.1% sodium citrate, pH 7.4, 0.1%
NP40, 9.65 mM NaCl, 200 mg/ml RNAse A, 50mg/ml PI)
and FACS analysis.
Immunoblotting
Whole cell protein extracts (lysis buffer: 30 mM
Tris–HCl pH 7.5, 150mMNaCl, 2 mM KCl, 2 mM EDTA,
5% Glycerol, 0.1% Triton X-100, and 1× Protease Inhi-
bitor Cocktail—Sigma-Aldrich, St. Louis, MO) were
quantiﬁed by BCA assay (Pierce, Rockford, IL), separated
onto NuPAGE 4–12% polyacrylamide gels (Invitrogen,
Carlsbad, CA) and blotted on nitrocellulose membranes
(Amersham, England). Membranes were hybridized with
polyclonal antibodies anti-PARP-1 (#9542 Cell Signaling
Technology, MA), anti-Caspase-3 (#9665 Cell Signaling
Technology), anti-PUMA/BBC3 (#4976 Cell Signaling
Technology, MA), anti-HSP90 (#4877 Cell Signaling
Technology, MA), anti-Lamin-A/C (#sc-6215 Santa Cruz
Biotechnology), anti-p21 (#sc-756, Santa Cruz Bio-
technology), anti-TP53INP1(#NBP1-76638 Novus-Biolo-
gicals) or monoclonal antibodies anti-Bcl-2 (#sc-509
Santa Cruz Biotechnology), anti-BTG2 (#SAB1404558
Sigma-Aldrich), and anti-p53 (#sc-126 Santa Cruz Bio-
technology). Monoclonal antibody either anti-Actin
(#CP01, Calbiochem) or anti-α-Tubulin (#T5168 Sigma-
Aldrich) was used as a loading control. Bands were
visualized and quantiﬁed with FluorChem E System
(Protein Simple, CA) or with ChemiDoc XRS+ and
ImageLabTM software (Bio-Rad Laboratories, Inc, Her-
cules, CA).
DNA constructs
PUMA/BBC3 3′UTR was PCR ampliﬁed from human
genomic DNA by using the following primers: PUMA/
BBC3-3′UTR-for 5′-GATCTCGAGCACTGACGGAG
ATCGCCA-3′, PUMA/BBC3-3′UTR-rev 5′-ATAGCGG
CCGCTCTACAGCAGCGATATACA-3′. The PCR frag-
ment was cloned downstream of the Renilla luciferase
gene in the psiCHECK-2 vector (Promega) by digestion
with XhoI and NotI. The mutant derivatives, lacking the
putative miR-663 binding sites, were generated from these
constructs by inverse PCR with the following primers:
PUMA/BBC3-Δ-for 5′-TTCCCATCAATCCCATTGCAT
AG-3′ and PUMA/BBC3-Δ-rev5′-TTCGGTCACGGGCA
GAGCACAGG-3′.
Short oligonucleotides (~70 nucleotides in length)
spanning the putative miR-663 binding sites within BTG2
3′UTR were designed as follows: BTG2-3′UTR-for5′-
TCGAGGAACTACGTGATGGCAGTCTCCAGCTAGG
CCCTTCCGCCCCCGCCCTGGGCGCCGCCGTGCTC
ATGCTGCCGTGGC-3′, BTG2-3′UTR-rev5′-GGCCGC
CACGGCAGCATGAGCACGGCGGCGCCCAGGGCA
CGTAGTTCC-3′. For the mutant derivatives,
oligonucleotides lacking the putative miR-663-binding
sites were used: BTG2-Δ-for5′-AGTCTCCAGC
TAGGCCCTTCC-3′ and BTG2-Δ-rev 5′-GGCCGCCAC
GGCAGCATGA GCACTGCCATCACGTAGTTCC-3′.
Brieﬂy, psiCHECK-2 vector was digested with XhoI and
NotI and its ends dephosphorylated with CIP (M0290S,
New England BioLabs) in order to prevent re-ligation of
the linearized vector. Each pair of oligos was annealed
upon phosphorylation with T4 PNK (Poly Nucleotide
Kinase—New England BioLabs) and cloned downstream
of the Renilla luciferase gene.
Luciferase reporter assay
In luciferase experiments, HeLa cells were seeded in 96-
well plate (4× 104 cells/well) and transfected with 40 ng
of Fireﬂy/Renilla luciferase vectors (empty psiCHECK-2,
psiCHECK-2-PUMA/BBC3 3′UTR wt or mutant,
psiCHECK-2-BTG2 3′UTR wt or mutant) together with
30 nM miR mimics (Qiagen, Germany). 0.2 µl/well of
Lipofectamine 2000 (Invitrogen) were used for transfec-
tion. The activity of both Fireﬂy and Renilla luciferases
was measured 72 h post-transfection using the Dual
Luciferase Assay kit (Promega) and the luminescence
plate reader Victor-X3 (Perkin Elmer, MA). Transfection
efﬁciency was normalized by calculating the ratio ﬁreﬂy/
renilla. The experiment was performed three times in
quadruplicate.
q-RT-PCR analysis
For mRNA analysis, NIH-H460 cells were treated with
10 nM LNA-663 for 92 h and total RNA was puriﬁed
with TRIZOL Reagent (Invitrogen) and reverse transcribed
with random primers (N6, Roche, Switzerland) and M-
MLV RT (Invitrogen) after DNase-I treatment (RQ1
DNase, Promega). Real-time PCR was performed with
SensiMix SYBR Hi-ROX (Bioline) for both SYBR Green-
and Taqman probes-based assays. BTG2 cDNA was
ampliﬁed using the following primers: BTG2-for 5′-
GCGTGAGCGAGCAGAGGCTT-3′ and BTG2-rev 5′-
GGCTGGCCACCCTGCTGATG-3′. PUMA/BBC3 cDNA
was ampliﬁed using a gene-speciﬁc Taqman probe assay
(Applied Biosystems, CA). For miR-663 analysis, we pro-
ceeded as in Pan et al.41 Brieﬂy, total RNA was puriﬁed
with TRIZOL Reagent and reverse transcribed with the
following miR-663-speciﬁc stem-loop primer: 5′- GTCG
TATCCAGTGCGTGTCGTGGAGTCGGCAATTGCAC
TGGATACGACGCGGTCC-3′. MiR-663 cDNA was
ampliﬁed using the following primers: miR-663-for
5′- GTGCGTGTCGTGGAGTCG-3′ and miR-663-rev
5′-TTTAGGCGGGGCG-3′.
Samples were run on an ABI PRISM 7900HT Sequence
Detection System (Applied Biosystems, CA) according to
standard procedures. Human GAPDH and U6-snRNA
were used as endogenous control.
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Immunoﬂuorescence
2× 104 NIH-H460 cells were seeded in each chamber
polystyrene vessel (BD Falcon) and transfected with LNA-
663 and relative control at the ﬁnal concentration of 50
nM. Seventy-two hours post-transfection the cell medium
was removed and cells were washed once with PBS and
ﬁxed in 2% paraformaldehyde for 10min at RT. Cells were
permeabilized by incubation with PBS+ 0.1% Triton
X-100 for 15 min at RT, and blocking was performed
using PBS+ 3% bovine serum albumin (BSA) for 1 h at
RT. Anti-BTG2 (#SAB1404558 Sigma-Aldrich) and
anti-PIN-1 (sc-15340 Santa Cruz Biotechnology, CA)
antibodies were used 1:100 in PBS+ 3% BSA. Goat anti-
Mouse IgG (H+ L) Alexa Fluor® 647 conjugate and Goat
anti-Rabbit IgG (H+ L) Alexa Fluor® 488 conjugate sec-
ondary antibodies (Life technologies) were diluted 1:1000
together with 1:20,000 DAPI (4′,6-Diamidino-2-Pheny-
lindole, Dihydrochloride, Life technologies) in PBS and
incubated with cells for 1 h at RT. Coverslips were then
mounted on glass slides with ProLong Gold Antifade
Mountant (Life technologies) and images were acquired
on a confocal microscope (Olympus, Japan). Nuclear and
cytoplasmic signals were quantiﬁed with ImageJ.
Measurement of mitochondrial membrane potential
Changes in the mitochondrial membrane potential
(ΔΨmt) were analyzed by ﬂow cytometry using the
ΔΨmt-sensitive dye 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetra-
ethylbenzimidazolylcarbocyanine iodide (JC-1, Molecular
probes, Life technologies). In highly polarized mitochon-
dria JC-1 accumulates as red ﬂuorescent aggregates.
Apoptosis results in a depolarization of the mitochondrial
membrane that disrupts JC-1 aggregates and can be
visualized as a decrease in the red ﬂuorescence and a shift
towards a green ﬂuorescence, yielded by the JC-1 mono-
mers. NIH-H460 cells were seeded in six-well plates and
transfected with LNA-663 and control LNA at the ﬁnal
concentration of 50 nM. Seventy-two hours post-trans-
fection, cells were trypsinized and counted; 1.5*105 cells
were harvested, washed once in PBS and incubated for 15
min at 37 °C upon addition of 5 µg/ml JC-1. After washing
twice in PBS, two ﬂuorescence parameters, ﬂuorescence
channel 1 (FL1) for green ﬂuorescence and ﬂuorescence
channel 2 (FL2) for red ﬂuorescence, were measured by
ﬂuorescence-activated cell sorting (FACS).
Subcellular fractionation
NIH-H460 cells were seeded in six-well plates and
treated with 25 nM LNA-663 or control LNA for 28 h.
1× 106 cells were harvested for subcellular fractionation.
For isolation of the mitochondrial fraction we used the
Qproteome Cell Compartment Kit (Qiagen) according to
a 1:5 scale-down of the manufacturer’s instructions.
Cytosolic proteins and proteins enriched in the plasma
membrane, as well as in all organelles (including mito-
chondria) were sequentially isolated in the F1 and F2
fractions, respectively. Proteins from fractions F1 and F2
were separated by SDS-PAGE and analyzed by Immuno-
blotting. The following proteins were detected as markers
speciﬁc for each fraction: HSP90 for the cytosolic fraction
and Bcl-2 for the mitochondria-containing fraction.
For the isolation of the nuclear and cytoplasmic frac-
tions to analyze PIN-1 localization we followed a different
protocol. First, the cytoplasmic protein extract was
obtained upon cell lysis with the following buffer, sup-
plemented with proteases inhibitors: 10 mM Hepes pH
7.5, 40 mM KCl, 3 mM MgCl2, 5% glycerol, and 0.2%
NP40. Then, nuclear extracts were obtained upon addi-
tion of the following buffer (supplemented with proteases
inhibitors) to the resulting pellet: 20 mM Hepes pH 7.5,
420mM NaCl, 1.5 mM MgCl2, 25% glycerol, 0.2 mM
EDTA, followed by three cycles of freezing and thawing to
disrupt nuclear membranes.
In vivo experiments
CD/1 female athymic nude mice were purchased from
The Jackson Laboratory and housed in groups of six or
less in isolated ventilated cages; food and water were
provided ad libitum. All animal procedures were per-
formed according to protocol approved by the Istituto
Superiore di Sanità Animal Care Committee.
2*105 NIH-H460 cells were subcutaneously injected
into the ﬂank of 6–8 weeks old mice. After one week,
when the tumors reached an average volume of 50 mm3,
the tumor bearing nude mice were treated with PBS or
LNA-663 at 15 mg/kg, by peri-tumoral injection two
times per week for 2 weeks. Tumor diameters were
measured at regular intervals as described above. Tumor
size was assessed every 2 days by caliper measurement.
Tumor volume was calculated as follows: D×d2×π/6,
where D and d are the longer and the shorter diameters,
respectively. PBS group n= 5; LNA-663 group n= 8.
Discussion
MiRs contribute to cancer onset and progression in
most human malignancies42. Some miRs can act as both
oncogenes and oncosuppressors in a tissue-dependent
manner as a consequence of differential gene expression
pattern determining speciﬁc miR-target interactions. The
dual role of miR-663 has been already documented in
recent literature reporting oncosuppressive activity in
glioblastoma43,44, pancreatic cancer45 and thyroid carci-
noma46, and supporting the oncogenic function of this
miR in prostate cancer47 and nasopharyngeal carci-
noma21. In lung cancer it was reported that miR-663 is
highly expressed in tumors compared to matched normal
tissues and a pro-proliferative role of the miR was
suggested48.
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In this study, we identiﬁed miR-663 as potential onco-
gene in NSCLC cells. We performed an unbiased
screening by monitoring miRs loss-of-function effect on
cancer cell viability and selected miR-663 among the top
hits. MiR-663 depletion resulted detrimental for lung
cancer cells, supporting a pro-tumoral activity in this
cellular context. This hypothesis was further veriﬁed in
four NSCLC cell lines and in patient-derived cells, har-
boring different histological origins and mutational status,
corroborating our previous ﬁndings. Furthermore, we
performed in vivo experiments to establish the ther-
apeutic potential of miR-663 ablation. We showed that
LNA-663 treatment signiﬁcantly reduces the growth of
tumor xenografts in immunodeﬁcient mice, providing
encouraging bases for further development of a new
therapeutic approach entailing miR-663 targeting. The
analysis of miR-663 expression on patient-derived speci-
mens did not reveal a higher expression in tumor versus
normal samples and no correlation with patient’s prog-
nosis was found when interrogating TCGA datasets.
Further, overexpression of miR-663 by a miR-mimic did
not increase lung cancer cells proliferation or resistance
to chemotherapy (data not shown). Based on these
observations, we conclude that miR-663 does not behave
as a driver gene in lung cancer onset and/or progression,
while it plays a key role in the control of apoptosis and is
therefore necessary for lung cancer homeostasis.
Deepening our analysis, we unraveled the mechanisms
of action of miR-663. We conﬁrmed p21 as target of this
microRNA, showing that it contributes to the control of
cell fate by miR-663 in NSCLC. Further, we report a rapid
induction of cell death following miR-663 neutralization
that is consistent with direct activation of MOMP effectors.
Interestingly, we found that miR-663 controls the escape
from apoptotic impulses by negatively regulating the
expression of two novel target genes: PUMA and BTG2.
We observed mitochondrial cell death induction upon miR-
663 depletion that was partially dependent on the function
of the BH3-only protein PUMA. Noteworthy, the upregu-
lation of PUMA is p53-independent as it does not occur at
transcriptional level. Consistently, PUMA accumulation
occurred also in p53-NULL cell lines such as Calu-1 and
H1299 cells thus explaining the effect of LNA-663 in this
background and and in p53-mutant patient-derived cells.
In a p53 wt background BTG2, the second target iden-
tiﬁed, cooperates with and empowers the action of PUMA
on MOMP induction. BTG2 is an early response gene
whose expression is induced upon several stress stimuli and
regulates cell differentiation, proliferation, DNA damage
repair, and apoptosis28. We recapitulated the mechanism of
apoptosis induction exerted by BTG2 through the interac-
tion with the cis–trans isomerase PIN-1, involving
p53 stabilization, and mitochondrial localization. Moreover,
we underlined the contribution of miR-663 upstream of
these events, showing how miR-663-dependent regulation
of BTG2 controls p53 mitochondrial translocation and by
that programmed cell death. In NSCLC-bearing mutant
p53, we found that BTG2 is not a relevant target of miR-
663. By silencing BTG2 in miR-663-depleted cells, we were
not able to rescue the induction of apoptosis, suggesting
that PUMA and possibly other targets of miR-663 mediate
the apoptotic cascade in the absence of p53.
Our data demonstrate that miR-663 has a determinant
role in apoptosis escape of NSCLC cells, thus sustaining
cancer progression. One of the hallmarks of cancer cells is
indeed the ability to escape control strategies meant to
avoid aberrancies and uncontrolled proliferation, such as
programmed cell death. Transformed cells are subjected
to a number of apoptotic stimuli and very often develop
alternative mechanisms to sustain cancer progression
including the inhibition of MOMP, which is a crucial step
of the intrinsic pathway of apoptosis11,49. BH3-only pro-
teins are pro-apoptotic factors that antagonize the pro-
survival members of the Bcl-2 protein family, which in
turn exert an inhibitory action on MOMP. Here we
showed how miR-663 controls MOMP induction by
directly targeting the BH3-only protein PUMA and
indirectly triggering a non-canonical function of p53,
which behaves as a BH3-only protein itself upon mito-
chondrial translocation. Pharmacological agents that
induce or facilitate MOMP represent attractive strategies
for cancer therapy. Notably, BH3-only proteins are key
effectors in the anti-cancer response to several therapeutic
approaches, such as tyrosine kinase inhibition, HDAC
inhibition, taxanes, glucocorticoids, and DNA-damaging
drugs. Further, small molecules that mimic BH3-only pro-
teins (BH3-mimetics) are currently under preclinical and
clinical development50,51. In particular, ABT-263 (navito-
clax), inhibitor of Bcl-2, Bcl-XL, and Bcl-W, and the less
toxic BH3-mimetic targeting only BCL-2, ABT-199 (vene-
toclax), hold great promise in combinatorial treatment of
several cancer types52,53. Our data support the development
of new approaches to modulate BH3-only effectors by
controlling the expression of miR-663 in NSCLC.
Acknowledgements
R.D.M. was supported by Italian Association for Cancer Research (AIRC)
(Investigator Grant 13431), Fundaciò La Maratò de TV3 (project 432/C/2013)
and Italian Ministry of Foreign Affairs and International Cooperation & Italian
Ministry of Education, University and Research to RDM (project PGR00674). L.V.
is supported by FIRC (Triennial Fellowship 2015). We thank Adriana Eramo for
sharing material, Mario Falchi for precious assistance with confocal imaging,
Alessandra Boe for FACS analyses and Stefano Forte for bio-statistical support.
Competing interests
The authors declare that they have no competing ﬁnancial interests.
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Fiori et al. Cell Death and Disease  (2018) 9:49 Page 12 of 13
Ofﬁcial journal of the Cell Death Differentiation Association
Supplementary information
The online version of this article (https://doi.org/10.1038/s41419-017-0080-x)
contains supplementary material.
Received: 7 June 2017 Revised: 10 October 2017 Accepted: 17 October
2017
References
1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin.
63, 11–30 (2013).
2. Izumchenko, E. et al. Targeted sequencing reveals clonal genetic changes in
the progression of early lung neoplasms and paired circulating DNA. Nat.
Commun. 6, 8258 (2015).
3. Alberg, A. J., Brock, M. V., Ford, J. G., Samet, J. M. & Spivack, S. D. Epidemiology
of lung cancer: diagnosis and management of lung cancer, 3rd ed: American
College of Chest Physicians evidence-based clinical practice guidelines. Chest
143, e1S–e129 (2013).
4. McIntyre, A. & Ganti, A. K. Lung cancer—a global perspective. J. Surg. Oncol.
115, 550–554 (2017).
5. Ha, M. & Kim, V. N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol.
15, 509–524 (2014).
6. Jonas, S. & Izaurralde, E. Towards a molecular understanding of microRNA-
mediated gene silencing. Nat. Rev. Genet. 16, 421–433 (2015).
7. Hayes, J., Peruzzi, P. P. & Lawler, S. MicroRNAs in cancer: biomarkers, functions
and therapy. Trends Mol. Med. 20, 460–469 (2014).
8. Lin, S. & Gregory, R. I. MicroRNA biogenesis pathways in cancer. Nat. Rev.
Cancer 15, 321–333 (2015).
9. Nana-Sinkam, S. P. & Croce, C. M. Clinical applications for microRNAs in cancer.
Clin. Pharmacol. Ther. 93, 98–104 (2013).
10. Cotter, T. G. Apoptosis and cancer: the genesis of a research ﬁeld. Nat. Rev.
Cancer 9, 501–507 (2009).
11. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell
144, 646–674 (2011).
12. Fiori, M. E. et al. Antitumor effect of miR-197 targeting in p53 wild-type lung
cancer. Cell Death Differ. 21, 774–782 (2014).
13. Yu, J., Zhang, L., Hwang, P. M., Kinzler, K. W. & Vogelstein, B. PUMA induces the
rapid apoptosis of colorectal cancer cells. Mol. Cell 7, 673–682 (2001).
14. Nakano, K. & Vousden, K. H. PUMA, a novel proapoptotic gene, is induced by
p53. Mol. Cell 7, 683–694 (2001).
15. Han, J. et al. Expression ofbbc3, a pro-apoptotic BH3-only gene, is regulated by
diverse cell death and survival signals. Proc. Natl. Acad. Sci. USA 98,
11318–11323 (2001).
16. Jeffers, J. R. et al. Puma is an essential mediator of p53-dependent and
-independent apoptotic pathways. Cancer Cell 4, 321–328 (2003).
17. Chipuk, J. E., Bouchier-Hayes, L., Kuwana, T., Newmeyer, D. D. & Green, D. R.
PUMA couples the nuclear and cytoplasmic proapoptotic function ofp53.
Science 309, 1732–1735 (2005).
18. Yu, J. & Zhang, L. PUMA, a potent killer with or without p53. Oncogene 27,
S71–S83 (2008).
19. Vousden, K. H. Apoptosis. p53 and PUMA: a deadly duo. Science 309,
1685–1686 (2005).
20. Beroukhim, R. et al. The landscape of somatic copy-number alteration across
human cancers. Nature 463, 899–905 (2010).
21. Yi, C. et al. MiR-663, a microRNA targeting p21(WAF1/CIP1), promotes the
proliferation and tumorigenesis of nasopharyngeal carcinoma. Oncogene 31,
4421–4433 (2012).
22. Okamura, S. et al. p53DINP1, a p53-inducible gene, regulates p53-dependent
apoptosis. Mol. Cell 8, 85–94 (2001).
23. Seillier, M. et al. TP53INP1, a tumor suppressor, interacts with LC3 and
ATG8-family proteins through the LC3-interacting region (LIR) and
promotes autophagy-dependent cell death. Cell Death Differ. 19, 1525–1535
(2012).
24. Tomasini, R. et al. TP53INP1s and homeodomain-interacting protein kinase-2
(HIPK2) are partners in regulating p53 activity. J. Biol. Chem. 278, 37722–37729
(2003).
25. Melamed, J., Kernizan, S. & Walden, P. D. Expression of B-cell translocation gene
2 protein in normal human tissues. Tissue Cell 34, 28–32 (2002).
26. Rouault, J. P. et al. Identiﬁcation of BTG2, an antiproliferative p53-dependent
component of the DNA damage cellular response pathway. Nat. Genet. 14,
482–486 (1996).
27. Guardavaccaro, D. et al. Arrest of G(1)-S progression by the p53-inducible gene
PC3 is Rb dependent and relies on the inhibition of cyclin D1 transcription.
Mol. Cell Biol. 20, 1797–1815 (2000).
28. Lim, I. K. TIS21 (/BTG2/PC3) as a link between ageing and cancer: cell cycle
regulator and endogenous cell death molecule. J. Cancer Res. Clin. Oncol. 132,
417–426 (2006).
29. Boiko, A. D. et al. A systematic search for downstream mediators of tumor
suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-
induced transformation. Genes Dev. 20, 236–252 (2006).
30. Struckmann, K. et al. Impaired expression of the cell cycle regulator BTG2 is
common in clear cell renal cell carcinoma. Cancer Res. 64, 1632–1638 (2004).
31. Kawakubo, H. et al. Loss of B-cell translocation gene-2 in estrogen receptor-
positive breast carcinoma is associated with tumor grade and overexpression
of cyclin d1 protein. Cancer Res. 66, 7075–7082 (2006).
32. Ficazzola, M. A. et al. Antiproliferative B cell translocation gene 2 protein is
down-regulated post-transcriptionally as an early event in prostate carcino-
genesis. Carcinogenesis 22, 1271–1279 (2001).
33. Hong, J. W., Ryu, M. S. & Lim, I. K. Phosphorylation of serine 147 of tis21/BTG2/
pc3 by p-Erk1/2 induces Pin-1 binding in cytoplasm and cell death. J. Biol.
Chem. 280, 21256–21263 (2005).
34. Sorrentino, G. et al. The prolyl-isomerase Pin1 activates the mitochondrial
death program of p53. Cell Death Differ. 20, 198–208 (2013).
35. Sorrentino, G., Comel, A., Mantovani, F. & Del Sal, G. Regulation of mito-
chondrial apoptosis by Pin1 in cancer and neurodegeneration. Mitochondrion
19, 88–96 (2014).
36. Marchenko, N. D. et al. Stress-mediated nuclear stabilization of p53 is regulated
by ubiquitination and importin-alpha3 binding. Cell Death Differ. 17, 255–267
(2010).
37. Marchenko, N. D., Wolff, S., Erster, S., Becker, K. & Moll, U. M. Monoubiquitylation
promotes mitochondrial p53 translocation. EMBO J. 26, 923–934 (2007).
38. Zacchi, P. et al. The prolyl isomerase Pin1 reveals a mechanism to control p53
functions after genotoxic insults. Nature 419, 853–857 (2002).
39. Leu, J. I., Dumont, P., Hafey, M., Murphy, M. E. & George, D. L. Mitochondrial p53
activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell. Biol. 6,
443–450 (2004).
40. Eramo, A. et al. Identiﬁcation and expansion of the tumorigenic lung cancer
stem cell population. Cell Death Differ. 15, 504–514 (2008).
41. Pan, J. et al. Tumor-suppressive mir-663 gene induces mitotic catastrophe
growth arrest in human gastric cancer cells. Oncol. Rep. 24, 105–112 (2010).
42. Croce, C. M. Causes and consequences of microRNA dysregulation in cancer.
Nat. Rev. Genet. 10, 704–714 (2009).
43. Shi, Y. et al. miR-663 suppresses oncogenic function of CXCR4 in glioblastoma.
Clin. Cancer Res. 21, 4004–4013 (2015).
44. Shi, Y. et al. Primate-speciﬁc miR-663 functions as a tumor suppressor by
targeting PIK3CD and predicts the prognosis of human glioblastoma. Clin.
Cancer Res. 20, 1803–1813 (2014).
45. Zang, W. et al. miR-663 attenuates tumor growth and invasiveness by tar-
geting eEF1A2 in pancreatic cancer. Mol. Cancer 14, 37 (2015).
46. Wang, Z., Zhang, H., Zhang, P., Dong, W. & He, L. MicroRNA-663 suppresses cell
invasion and migration by targeting transforming growth factor beta 1 in
papillary thyroid carcinoma. Tumour Biol. 37, 7633–7644 (2015).
47. Jiao, L. et al. miR-663 induces castration-resistant prostate cancer transfor-
mation and predicts clinical recurrence. J. Cell. Physiol. 229, 834–844 (2014).
48. Liu, Z. Y., Zhang, G. L., Wang, M. M., Xiong, Y. N. & Cui, H. Q. MicroRNA-663
targets TGFB1 and regulates lung cancer proliferation. Asian Pac. J. Cancer Prev.
12, 2819–2823 (2011).
49. Evan, G. I. & Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer.
Nature 411, 342–348 (2001).
50. Fulda, S., Galluzzi, L. & Kroemer, G. Targeting mitochondria for cancer therapy.
Nat. Rev. Drug Discov. 9, 447–464 (2010).
51. Delbridge, A. R. & Strasser, A. The BCL-2 protein family, BH3-mimetics and
cancer therapy. Cell Death Differ. 22, 1071–1080 (2015).
52. Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves
antitumor activity while sparing platelets. Nat. Med. 19, 202–208 (2013).
53. Ashkenazi, A., Fairbrother, W. J., Leverson, J. D. & Souers, A. J. From basic
apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat. Rev.
Drug Discov. 16, 273–284 (2017).
Fiori et al. Cell Death and Disease  (2018) 9:49 Page 13 of 13
Ofﬁcial journal of the Cell Death Differentiation Association
